Vericel's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was €-0.10.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.37.
Vericel's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.10.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.36.
Vericel's EPS without NRI for the
three
months ended in Mar. 2026 was €-0.10.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.36.
During the past 12 months, Vericel's average EPS without NRIGrowth Rate was 1300.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Vericel's highest 3-Year average EPS without NRI Growth Rate was 62.30% per year. The lowest was -16.70% per year. And the median was 15.70% per year.
Vericel (FRA:ATQP) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Vericel EPS (Basic) Related Terms
Vericel EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Vericel's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Vericel's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (FRA:ATQP) has a EPS (Basic) of €0.37 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vericel and its competitors.
Is Vericel's EPS (Basic) too high?
Vericel's current EPS (Basic) is €0.37. Overall, Vericel has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's EPS (Basic) compare to PVLA and TSHA?
Vericel's EPS (Basic) of €0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Vericel and its competitors. Vericel's current EPS (Basic) is €0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (FRA:ATQP) is currently considered Modestly Undervalued. The stock's GF Value™ is €46.10, compared to a current price of €35.40 — trading 23.2% below its estimated fair value. The current EPS (Basic) is €0.37. Vericel's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current EPS (Basic) is €0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (FRA:ATQP) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of €35.40 is trading 23.2% below its estimated GF Value™ of €46.10.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for FRA:ATQP:
EPS (Basic): €0.37
GF Value™: €46.10 vs. price of €35.40 (23.2% below fair value)
No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
72GF Score
Get the complete analysis for FRA:ATQP
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ATQP has been successfully added to your 
